Brooks Laboratories Limited (BOM:533543)

Market Cap	2.04B
Revenue (ttm)	927.94M
Net Income (ttm)	139.72M
Shares Out	n/a
EPS (ttm)	4.92
PE Ratio	14.60
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,002
Average Volume	5,801
Open	72.33
Previous Close	71.86
Day's Range	70.28 - 73.46
52-Week Range	69.05 - 180.95
Beta	n/a
RSI	24.16
Earnings Date	Feb 12, 2026

About Brooks Laboratories

Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company’s product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and dry powder injections; formulations for antibiotics, pain management, and controlled drugs; and oncology products and hormonal injections, etc. It also ...

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 323
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 533543

Financial Performance

In 2024, Brooks Laboratories's revenue was 825.57 million, an increase of 3.86% compared to the previous year's 794.86 million. Losses were -99.67 million, -49.13% less than in 2023.